CTSO Cytosorbents Corp Insider Trading

CFO Peter J Mariani buys 100.0K shares of CTSO at $0.44; stock down 69.1% from 52-week high, company unprofitable with -$5.1M net income.

CFO Peter J Mariani purchased 100,000 shares at $0.44 on 2026-06-15, increasing his holdings by 18.6% to 638.1K shares, while the stock trades at $0.43 — down 69.1% from its 52-week high and down 13.6% over the prior 30 days. His prior three purchases at CTSO (made in December 2024) each posted positive 90-day returns ranging from +10.9% to +19.7%, suggesting a pattern of well-timed accumulation at this ticker. However, the company reported a net loss of $5.1M against quarterly revenue of $8.9M, and the broader fundamentals remain unprofitable on an annual basis despite 4.1% year-over-year revenue growth. The transaction occurs as the stock trades near multi-year lows, and the CFO's historical success at timing CTSO entries warrants attention to whether this purchase reflects a contrarian view of value or simply continuation of a long-standing accumulation pattern in a structurally challenged business.

CEO Phillip P. Chan purchases 261,469 shares at blended $0.40 avg; stock down -69.1% from 52-week high, company unprofitable ($-5.1M net income).

Phillip P. Chan, CEO of Cytosorbents Corp, executed 2 separate open-market purchases totaling 261,469 shares for $104,897.59 on 2026-06-12 and 2026-06-15, expanding his holdings by +17.6% to 1,744,432 shares. The blended purchase price of $0.40 is below the current price of $0.43, but the stock has declined -69.1% from its 52-week high of $1.39 and is down -36.8% over the past 90 days. Cytosorbents is unprofitable with net income of $-5.1M against quarterly revenue of $8.9M. His prior CTSO purchase on 2023-12-13 experienced a -24.8% 90-day return, showing no pattern of well-timed entry signals at this ticker. The combination of sustained unprofitability, severe price deterioration, and a prior poorly-timed accumulation at the same company warrants scrutiny of the financial and strategic context surrounding this transaction.

CFO MARIANI buys 20,000 shares of CTSO at $0.96 on 2024-12-13, now down -50.5% from 52-week high

MARIANI PETER J, the CFO, purchased 20,000 shares at $0.96, bringing his holdings to 401,363 shares (+5.2% increase). The transaction occurs in a context of significant price deterioration: the stock is -50.5% from its 52-week high of $1.84 and has declined -31.1% over the past 90 days, though it has recovered +1.7% in the last 30 days. The company remains unprofitable, reporting net income of $-2.3M in the latest quarter against revenue of $9.4M, though annual revenue growth stands at +4.8%. This purchase follows two other buys by MARIANI at CTSO on consecutive days (2024-12-12 and 2024-12-11), suggesting accumulation behavior during a depressed price period. His cross-ticker track record shows 2 prior buys, but outcomes for same-ticker purchases cannot yet be measured. The clustering of three buys within a narrow window while the stock trades well below recent highs warrants attention to whether fundamentals are stabilizing or whether the CFO has specific conviction regarding valuation.

CFO MARIANI buys 31,363 shares ($28.0K) at $0.89 across 2 transactions; holdings rise 9.0% as CTSO trades -45.1% from 52-week high

MARIANI PETER J, Chief Financial Officer, executed 2 separate purchases totaling 31,363 shares for $27,974.84 at $0.89 per share on 2024-12-11 and 2024-12-12, raising his holdings from 350,000 to 381,363 shares (a 9.0% increase). The purchases occurred at a price point 11.9% below the current $1.01 level and represent a notable accumulation given that CTSO trades -45.1% from its 52-week high of $1.84, following a 30-day rally of +9.1%. Against the backdrop of the company's unprofitable full-year position (net income of $-2,334,091.00 in the latest quarter) and $55.2M market cap, the timing of this open-market accumulation at depressed prices warrants investor attention. The CFO's willingness to deploy capital into company shares during a period of net losses and elevated distance from recent highs provides a data point on insider perspective regarding valuation and near-term outlook.